Literature DB >> 22836760

Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema.

Carsten Framme1, Paul Schweizer, Manfred Imesch, Sebastian Wolf, Ute Wolf-Schnurrbusch.   

Abstract

PURPOSE: Hyperreflective foci (HFs) are observable within the neurosensory retina in diabetic macular edema (DME) using spectral domain optical coherence tomography (SD-OCT). HFs have also been seen in wet age-related macular degeneration (AMD), although the origin is still unknown; however, they reduced significantly during anti-VEGF (vascular endothelial growth factor) therapy, and their baseline amount seemed to correlate with treatment success. In this study the behavior of HFs was evaluated during anti-VEGF therapy for DME.
METHODS: Fifty-one patients (mean age: 67 years) underwent SD-OCT before and one month after one anti-VEGF injection (ranibizumab: n = 30; bevacizumab: n = 21). The HFs were semiquantitatively counted, assigned to three groups (group A: HFs n = 1-10; group B: n = 11-20; group C: n > 20), and correlated to the course of visual acuity and foveal thickness (paired t-test). Additionally the baseline HbA1c was categorized and correlated to baseline HFs (Spearman Rho).
RESULTS: In all eyes, HFs of various amounts were detected in the foveal and parafoveal area. The mean number of HFs reduced significantly from 16.02 to 14.32 in all patients (P = 0.000), whereas foveal thickness reduced from 445.5 to 373.9 μm (P = 0.000) and visual acuity increased from 62.0 to 66.0 ETDRS letters (P = 0.003). Regarding the three HF groups, a reduction of the level stages was observed in 43.1% (stable: 54.9%; more: 2.0%). This reflects a HF distribution change from 31.4% to 62.7% (group A), from 45.1% to 31.4% (group B), and from 23.5% to 5.9% (group C). The HbA1c correlated significantly to the overall HF amount at baseline (0.880; P = 0.000); however, no distinct overall correlation was found between the HF reduction and the course of visual acuity or retinal thickness. Only in cases of complete edema resolution (25%) did HFs reduce significantly (P = 0.008).
CONCLUSIONS: As in wet AMD, HFs are frequently found in DME and behave similarly under anti-VEGF therapy. Thus, a HF reduction was observable mainly in cases of complete edema resolution; however, no distinct correlation with visual acuity was noticed, presumably mainly due to the enhanced inhomogeneity in the disease progress of DME. Interestingly, the baseline HF amount seems to correlate positively with HbA1c values indicating the severity of disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836760     DOI: 10.1167/iovs.12-9950

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  49 in total

Review 1.  Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.

Authors:  Gianni Virgili; Francesca Menchini; Giovanni Casazza; Ruth Hogg; Radha R Das; Xue Wang; Manuele Michelessi
Journal:  Cochrane Database Syst Rev       Date:  2015-01-07

2.  Evaluation of hyperreflective foci as a prognostic factor of visual outcome in retinal vein occlusion.

Authors:  Bin Mo; Hai-Ying Zhou; Xuan Jiao; Feng Zhang
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

3.  Automated segmentation of hyperreflective foci in spectral domain optical coherence tomography with diabetic retinopathy.

Authors:  Idowu Paul Okuwobi; Wen Fan; Chenchen Yu; Songtao Yuan; Qinghuai Liu; Yuhan Zhang; Bekalo Loza; Qiang Chen
Journal:  J Med Imaging (Bellingham)       Date:  2018-02-06

4.  Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema.

Authors:  Tomoaki Murakami; Kiyoshi Suzuma; Akihito Uji; Shin Yoshitake; Yoko Dodo; Masahiro Fujimoto; Tatsuya Yoshitake; Yuko Miwa; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2018-02-19       Impact factor: 2.447

5.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

6.  Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion.

Authors:  Joon-Won Kang; Hyungwoo Lee; Hyewon Chung; Hyung Chan Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-01       Impact factor: 3.117

7.  En face Integrated Central Avascular Zone (EFICAZ): a noninvasive tool for correlating morphological and functional damage in central diabetic macular edema.

Authors:  Joel Hanhart; Israel Strassman; Yaakov Rozenman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-30       Impact factor: 3.117

8.  OPTICAL COHERENCE TOMOGRAPHY CHARACTERISTICS OF MACULAR EDEMA AND HARD EXUDATES AND THEIR ASSOCIATION WITH LIPID SERUM LEVELS IN TYPE 2 DIABETES.

Authors:  Samaneh Davoudi; Evangelia Papavasileiou; Ramak Roohipoor; Heeyoon Cho; Shreyas Kudrimoti; Heather Hancock; Suzanne Hoadley; Christopher Andreoli; Deeba Husain; Maurice James; Alan Penman; Ching J Chen; Lucia Sobrin
Journal:  Retina       Date:  2016-09       Impact factor: 4.256

9.  Predictors for 2-Year Functional and Morphological Outcomes of a Treat-and-Extend Regimen with Ranibizumab in Patients with Diabetic Macular Edema.

Authors:  Helena Giannakaki-Zimmermann; Alexandra Behrndt; Laura Hoffmann; Maria-Magdalena Guichard; Cengiz Türksever; Christian Prünte; Katja Hatz
Journal:  Ophthalmic Res       Date:  2021-01-26       Impact factor: 2.892

10.  OCT Hyperreflective Retinal Foci in Diabetic Retinopathy: A Semi-Automatic Detection Comparative Study.

Authors:  Edoardo Midena; Tommaso Torresin; Erika Velotta; Elisabetta Pilotto; Raffaele Parrozzani; Luisa Frizziero
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.